Cycrin contains medroxyprogesterone as its active component. It is a synthetic progestin belonging to the class of hormones used in women's health. The medication is supplied as a pill in two strengths: 5 mg and 10 mg. In Hong Kong, Cycrin is a prescription-only product and is regulated by the Hong Kong Department of Health.
Medroxyprogesterone mimics the activity of the natural hormone progesterone. By binding to progesterone receptors in the uterus, breast, and brain, it helps regulate the menstrual cycle and alters the hormonal environment. The drug’s actions include:
Because medroxyprogesterone is taken orally, it is absorbed through the gastrointestinal tract, reaches peak blood levels within a few hours, and has a half-life of approximately 12-14 hours. The medication is metabolized primarily in the liver and excreted in the urine.
Cycrin is approved in Hong Kong for the following indications:
These uses reflect the drug’s ability to provide progestogenic activity that balances estrogen effects and controls uterine lining proliferation.
Scientific literature reports some off-label investigations of medroxyprogesterone, but none are approved by regulatory agencies in Hong Kong. Examples include:
These applications are not approved, and any off-label use requires careful medical supervision and individualized risk assessment.
Absolute contraindications
Relative contraindications
Special populations
If any of these conditions apply, discuss alternatives with a healthcare professional.
Patients should provide a complete medication list, including over-the-counter drugs, supplements, and herbal products, before starting Cycrin.
This article provides educational information about Cycrin and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Breakthrough bleeding can occur during the first few months of therapy as the body adjusts. Record the frequency and volume, and contact your healthcare provider if bleeding is heavy, prolonged, or accompanied by pain.
Cycrin provides progestogenic activity, but it is not approved as a sole contraceptive in Hong Kong. For reliable birth control, it should be combined with estrogen or used alongside another approved method.
Cycrin’s active ingredient, medroxyprogesterone, has a longer half-life and stronger receptor affinity compared with some other synthetic progestins. This allows once-daily dosing, but individual response varies.
Yes, provided you carry the medication in its original packaging with a copy of the prescription. Some countries may require a doctor’s note for hormonal medications, so check local regulations before departure.
There are no specific food restrictions. However, a balanced diet supports overall hormonal health, and excessive alcohol should be limited to reduce liver strain.
Progestins do not interfere with the detection of human chorionic gonadotropin (hCG) in standard urine tests, so the test remains reliable.
Typical excipients include lactose, microcrystalline cellulose, and magnesium stearate. If you have known allergies to these substances, verify the full ingredient list with your pharmacist.
Most women notice a more regular pattern within 2-3 months, though full stabilization may require up to six cycles.
Yes, medroxyprogesterone is commonly paired with estrogen in HRT to protect the uterine lining. The combination dose should be prescribed by a clinician.
Progestins can stimulate estrogen-sensitive tissues; therefore, Cycrin is generally contraindicated in women with active or a history of estrogen-dependent breast cancer. Alternative therapies should be explored.
